Halofuginone promotes satellite cell activation and survival in muscular dystrophies  by Barzilai-Tutsch, Hila et al.
Biochimica et Biophysica Acta 1862 (2016) 1–11
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isHalofuginone promotes satellite cell activation and survival in
muscular dystrophiesHila Barzilai-Tutsch a, Anna Bodanovsky a, Hadar Maimon a, Mark Pines b, Orna Halevy a,⁎
a Department of Animal Sciences, The Hebrew University of Jerusalem, Rehovot 76100, Israel
b Institute of Animal Science, The Volcani Center, Bet Dagan 52505, IsraelAbbreviations: BrdU, 5-bromo-2′-deoxyuridine;
Duchenne MD; DMEM, Dulbecco's Modiﬁed Eagle's Med
regulated protein kinase; DAPI, 4′,6-diamidino-2-ph
activated protein kinase; MDs, muscular dystroph
phosphoinositide 3 kinase; PPH3, phospho-histone H3; TG
β; YY1, Ying-Yang 1.
⁎ Corresponding author at: Dept. of Animal Scienc
Jerusalem, P.O. Box 12, Rehovot 76100, Israel.
E-mail address: orna.halevy@mail.huji.ac.il (O. Halevy
http://dx.doi.org/10.1016/j.bbadis.2015.10.007
0925-4439/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 July 2015
Received in revised form 5 October 2015
Accepted 6 October 2015
Available online 8 October 2015
Keywords:
Muscular dystrophy
Apoptosis
Cell cycle
Satellite cell
Myoﬁber
HalofuginoneHalofuginone is a leading agent in preventing ﬁbrosis and inﬂammation in various muscular dystrophies. We
hypothesized that in addition to these actions, halofuginone directly promotes the cell-cycle events of satellite
cells in the mdx and dysf−/− mouse models of early-onset Duchenne muscular dystrophy and late-onset
dysferlinopathy, respectively. In both models, addition of halofuginone to freshly prepared single gastrocnemius
myoﬁbers derived from 6-week-old mice increased BrdU incorporation at as early as 18 h of incubation, as well
as phospho-histone H3 (PHH3) and MyoD protein expression in the attached satellite cells, while having no
apparent effect on myoﬁbers derived from wild-type mice. BrdU incorporation was abolished by an inhibitor
of mitogen-activated protein kinase/extracellular signal-regulated protein kinase, suggesting involvement
of this pathway in mediating halofuginone's effects on cell-cycle events. In cultures of myoﬁbers and
myoblasts isolated from dysf−/− mice, halofuginone reduced Bax and induced Bcl2 expression levels
and induced Akt phosphorylation in a time-dependent manner. Addition of an inhibitor of the
phosphinositide-3-kinase/Akt pathway reversed the halofuginone-induced cell survival, suggesting
this pathway's involvement in mediating halofuginone's effects on survival. Thus, in addition to its
known role in inhibiting ﬁbrosis and inﬂammation, halofuginone plays a direct role in satellite cell activ-
ity and survival in muscular dystrophies, regardless of the mutation. These actions are of the utmost im-
portance for improving muscle pathology and function in muscular dystrophies.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The adult muscle tissue is composed of terminally differentiated
mature myoﬁbers [reviewed in 1,2]. In cases of acute stress such
as injury, or under myopathic conditions, the myoﬁbers' ability
to regenerate and repair relies solely on the myogenic capacity of
the muscle progenitor cells, the satellite cells [reviewed in 3].
These cells, normally quiescent, are situated in a niche between
the sarcolemma and the basal lamina of the myoﬁber. In response
to stress (e.g., mechanical stress, injuries, myopathies), appropriate
stimulatory signals such as hepatocyte growth factor and nitric
oxide (NO) [4–6] activate the satellite cells from their quiescent
state. The cells are driven into the cell cycle and after severalCMD, congenital MD; DMD,
ium; ERK, extracellular signal-
enylindole; MAPK, mitogen-
ies; NO, nitric oxide; PI3K,
Fβ, transforming growth factor
es, The Hebrew University of
).cell divisions, they exit the cell cycle and undergo myogenic differ-
entiation, subsequently fusing with pre-existing or new myoﬁbers
[reviewed in 2,7].
In Duchenne muscular dystrophy (DMD), characterized by
near absence of the protein dystrophin in skeletal muscles [8], the
myoﬁbers undergo repetitive cycles of degeneration–regeneration
followed by a rise in inﬂammation and ﬁbrosis and exhaustion
of the satellite cell population [9,10, reviewed in 11]. For example,
in a 9-year-old DMD patient, the proliferative life span of satellite
cells was approximately one-third that of an age-matched control
[12]. In contrast to DMD which evolves in early childhood,
dysferlinopathy is an autosomal recessive late-onset MD with a mu-
tation in the dysferlin gene that appears in patients between the ages
of 20 to 30 years [13,14]. Though not characterized by the aggressive
degeneration–regeneration cycles of DMD, similar cycles have been
shown to occur along with a signiﬁcant rise in inﬂammation and
ﬁbrosis [15–17].
Apoptosis has been shown to increase and become a leading
cause of myoﬁber degradation following necrosis [reviewed in 18,
19] under acute stress such as electrical stimulation [20], in chronic
conditions such as cachexia [21], in aging [22], and in MDs [11,23].
In mdx mice and DMD patients, upregulation of pro-apoptotic
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suggesting that under pathological conditions, these myoﬁbers
undergo apoptosis [11]. Detection of apoptosis and decreased Bcl2
expression have been observed in patients with other MDs, such as
Limb Girdle MD type 2C [24] and congenital MD (CMD) type 1A
[25]. In agreement with others [11,19,21], we recently reported
that in the mdx mouse model of DMD, the diaphragm, which is the
muscle that is most affected by this disease, the number of apoptotic
satellite cells andmacrophages is higher than in wild-type mice [26].
In contrast, myoﬁbroblasts, the activated form of ﬁbroblasts, become
resistant to apoptosis in dystrophic muscles [26–28]. Thus far, to the
best of our knowledge, the presence of apoptosis has not been
investigated in dysferlinopathies.
Halofuginone, an inhibitor of Smad3 phosphorylation down-
stream of the transforming growth factor β (TGFβ) signaling
pathway, results in inhibition of the ﬁbroblast-to-myoﬁbroblast
transition and ﬁbrosis [29], reviewed in [30], and prolyl-tRNA syn-
thetase activity results in inhibition of Th17 cell differentiation,
thereby inhibiting inﬂammation [31,32]. Halofuginone has been
reported to improve muscle histopathology in mouse models
with early disease onset, such as mdx and the laminin α2-deﬁcient
dy2J/dy2J mouse model of CMD [33,34], reviewed in [35]. More re-
cently, it has been reported that halofuginone also improves muscle
histopathology and function in a dysferlin-knockout mouse model,
through a direct effect on muscle cells. It promotes myotube fusion
of primary myoblasts derived from normal and dystrophic muscles
[36], and inhibits apoptosis of satellite cells and myoﬁbers in the
mdx mouse muscle [26]. Halofuginone promotes the phosphoryla-
tion of Akt and mitogen-activated protein kinase (MAPK) family
members, and enhances the association of phosphorylated Akt and
MAPK/extracellular signal-regulated protein kinase (MAPK/ERK)
with the nonphosphorylated form of Smad3, resulting in decreased
Smad3 phosphorylation [36]. Both MAPK/ERK and phosphoinositide
3 kinase (PI3K)/Akt pathways are involved in the myogenic lineage;
the MAPK/ERK pathway has been reported to be mainly involved in
early stages of myoblast proliferation [37,38], while the PI3K/Akt
pathway has been shown to be crucial for later stages of their
terminal differentiation and for cell survival [39–41].
The promotive effect of halofuginone on the MAPK/ERK pathway
prompted us to look into its effect on cell-cycle events of satellite
cells in mouse models of dysferlinopathy and DMD. Halofuginone
promoted the entrance of single-myoﬁber-attached satellite cells
into the cell cycle via the MAPK/ERK pathway. Moreover, the
increased apoptosis in myoﬁbers and myoblasts of the dysferlin-
deﬁcient mouse model was reduced by halofuginone treatment via
the PI3K/Akt pathway.
2. Materials and methods
2.1. Reagents
Dulbecco's Modiﬁed Eagle's Medium (DMEM), sera and antibiotic-
antimycotic solution were purchased from Biological Industries
(Beit-Haemek, Israel). Ly294002 and UO127 were purchased from
Calbiochem (Gibbstown, NJ). Halofuginone bromohydrate was
obtained from Akashi Therapeutics, LLC (Newton, MA).
2.2. Mice
Male dysf −/− [mixed 129SvJ and C57/BL/g background (Stock
006,830) in which a 12-kb region of the dysf gene containing
the last three exons is deleted, removing the transmembrane
domain], mdx [C57BL/10ScSn-Dmdmdx/J (Stock 001,801), dystrophin-
deﬁcient)] and C57/Bl/6 J (termedWt or C57)mice (Jackson Laboratories,
Bar Harbor, ME) were housed in cages under constant photoperiod
(12 L:12 D) with free access to food and water. All animalexperiments were carried out according to the guidelines of the
Volcani Center Institutional Committee for Care and Use of Laborato-
ry Animals (IL-234/10).
2.3. Cell preparation and maintenance
Primary myoblasts from the hind-leg muscles of 6-week-old
mice were prepared as described previously [42]. Cells were plated at
a low density of 3 x 105 in Petri dishes (90 mm diameter) to avoid
spontaneous differentiation and grown at similar rate in DMEM
supplemented with 20% (v/v) fetal calf serum (FCS) at 37.5 °C with
humidiﬁed atmosphere and 5% CO2 in air.
2.4. Single myoﬁber preparation and immunostaining
Single myoﬁbers were isolated from the gastrocnemius muscle
as described previously [26]. Brieﬂy, six mice were sacriﬁced and
the gastrocnemius muscles (6–7 muscles) were carefully removed.
The outer connective tissue was removed and groups of three
muscles were immersed in a 2.5-ml solution of 0.28% (w/v) collage-
nase type I in DMEM for 60 min for Wt and mdx mice, or for 90 min
for dysf −/− mice. The collagenase-treated muscle was then trans-
ferred to horse serum (HS)-coated Petri dishes containing 10 ml of
DMEM with 10% (v/v) HS for full coverage of the digested ﬁbers,
and triturated with a wide-mouth pipette. Myoﬁbers were then
washed three times with 10 ml DMEM with 10% HS and placed in
90-mm gelatin-coated plates and remained ﬂoating. Trypan blue
staining revealed that almost 100% of these myoﬁbers were viable
(data not shown). For immunostaining, the myoﬁbers were trans-
ferred to 35-mm plates, ﬁxed with 4% paraformaldehyde and then
incubated with Triton X-100 (0.5% v/v in PBS) and blocked with
20% (v/v) goat serum (GS) in PBS. The myoﬁbers were incubated
overnight at 4 °C with the following polyclonal antibodies: anti-Bax
(1:150, Santa Cruz Biotechnology), anti-Bcl2 (1:150, Calbiochem),
anti-phospho-histone H3 (PHH3), anti-phospho-Akt and anti-
phospho-p42/44 (each at 1:1000 dilution, Cell Signaling, Beverly,
MA), and monoclonal anti-MyoD (1:150, Santa Cruz Biotechnology),
followed by incubation with Alexa 594 goat anti-rabbit IgG or Alexa
488 goat anti-rabbit IgG (1:300, Jackson Laboratories) secondary
antibody for 1 h at room temperature. Nuclei were then stained
with 4′,6-diamidino-2-phenylindole (DAPI; Sigma Aldrich, St. Louis,
MO) in PBS. The myoﬁbers were visualized under a ﬂuorescence
microscope (Olympus, Hamburg, Germany) with a DP-11 digital
camera (Olympus). Negative control stainingwithout the ﬁrst antibody
revealed some autoﬂuorescence of the myoﬁber, but with no nucleus
staining (data not shown).
2.5. 5-Bromo-2′-deoxyuridine (BrdU) incorporation
Single myoﬁbers were cultured for 6 h in DMEM containing 10 μM
BrdU (Sigma) and immunostained with mouse anti-BrdU antibody
(G3G4, 1:2000, Becton Dickinson). Cultures were ﬁxed in 2%
paraformaldehyde for 15 min and then incubated with Triton
X-100 (0.5% in PBS) and blocked with 5% GS and 1% HS in PBS. The
cultures were incubated in 2 N HCl/0.2% Triton X-100 in double-
distilled water for 10 min at room temperature followed by 5 min
in 50 nM glycine in PBS. Incubation of myoﬁbers with mouse anti-
BrdU antibody was followed by incubation with biotinylated donkey
anti-mouse IgG (1:250, Jackson Laboratories) for 1 h and in Texas Red
streptavidin (1:300, Jackson Laboratories) for 30 min. Nuclei were
stained with DAPI.
2.6. Western blot analysis
Western blot analysis was performed as described previously [43].
Brieﬂy, equal amounts of protein (30 μg or 40 μg for myoblasts or
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transferred to nitrocellulose membranes (Bio-Rad). After blocking,
themembranes were incubated with the following primary antibodies:
rabbit polyclonal anti-Bax, rabbit polyclonal anti-Ying-Yang
1 (YY1, 1:500, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Akt,
anti-phospho-Akt, anti-phospho-p42/44 and anti-p42/44 (each atFig. 1. BrdU expression in cells associated to myoﬁbers derived from wild-type (C57; A),mdx (
mice were untreated (Cont) or treated with 10 nM halofuginone (Halo) for 18, 24 and 48 h. B
Nuclei were stainedwith DAPI. Arrows indicate BrdU-positive cells. Quantitation analysis of BrdU
cells per myoﬁber (n = 30 myoﬁbers per treatment). *Signiﬁcant difference within each time1:1000, Cell Signaling). The secondary antibody used was polyclonal
horse reddish peroxidase-conjugated goat anti rabbit (1:6000, Zymed,
San Francisco, CA). Densitometric analysis was performed on bands
using Gel-Pro Analyzer v3.0 software (Media Cybernetics Inc., Silver
Spring, MD) software. Band intensity in each lane was normalized to
the level YY1 as an internal standard [26].B) and dysf−/− (C) mice. Single myoﬁbers isolated from the gastrocnemius of 6-week-old
rdU (10 μM) was added for the last 6 h and then myoﬁbers were stained for its presence.
-positive cells in C57 (D),mdx (E) and dysf−/− (F)myoﬁbers is presented as BrdU-positive
point at P b 0.05. Please note the different y-axis scales in D–F.
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The data were subjected to one-way analysis of variance and to
all-pairs Tukey-Kramer HSD test using JMP® software [44].
3. Results
3.1. Halofuginone increases cell-cycle activity and MyoD expression in cells
associated with single dystrophic myoﬁbers
Cell-cycle phases were evaluated using BrdU, a marker for DNA
replication during the S-phase, and PHH3, a marker for M-phase entry.
Single myoﬁbers were prepared from the gastrocnemius muscle of
6-week-old Wt (C57), mdx and dysf−/− mice and were immediately
treated, or untreated with 10 nM halofuginone for various times. BrdU
was added for the last 6 h followed by immunoﬂuorescence assay for
its incorporation into DNA (Fig. 1).
Hardly any nuclei were stained for BrdU immediately after myoﬁber
preparation (data not shown). After 18 h, a few BrdU-positive nuclei
per myoﬁber were detected in all nontreated myoﬁbers (Fig. 1A–C),
suggesting the activation and cell-cycle entrance of single-myoﬁber-
associated satellite cells [45,46]. Moreover, the number of BrdU-
positive nuclei per myoﬁber increased at later time points in all
myoﬁbers (Fig. 1D-F), but was much lower in C57 vs. dystrophic
myoﬁbers. This was consistent with previous reports of Wt satellite
cells being largely quiescent under steady-state conditions, as op-
posed to dystrophic muscles in which there is ongoing tissue regen-
eration due to genetic disorders [47–49]. Some reduction in dysf−/−
BrdU-positive nuclei was observed after 48 h (Fig. 1F). The number of
nuclei expressing BrdU in the halofuginone-treated C57 myoﬁbers
did not differ from that in the control untreated myoﬁbers at any
time point (Fig. 1A,D). However, single mdx myoﬁbers treated with
halofuginone demonstrated a signiﬁcant rise in the number of
BrdU-positive nuclei per myoﬁber relative to controls at all time-
points, reaching approximately threefold already after 18 h of incu-
bation (Fig. 1B,E). Halofuginone-treated dysf−/− myoﬁbers demon-
strated an approximately twofold rise in BrdU-positive nuclei per
myoﬁber at 18 h and 48 h compared to controls, with no signiﬁcant
difference after 24 h (Fig. 1C,F).
Immunoﬂuorescence staining for PHH3 in untreated single C57 and
dysf−/− myoﬁbers demonstrated an increase in PHH3-positive nuclei
between 24 and 48 h of incubation (Fig. 2). Halofuginone treatment of
C57 myoﬁbers had no effect on the number of PHH3-positive cells per
myoﬁber at either time point (Fig. 2B). However, in dysf−/−myoﬁbers,
a nearly signiﬁcant increase (P = 0.053) in the number of PHH3-
positive nuclei per myoﬁber was observed in response to halofuginone
at 24 h compared to nontreated myoﬁbers, which became signiﬁcant at
48 h (Fig. 2C).
The expression of MyoD, a bona ﬁde marker for activated satellite
cells on isolated myoﬁbers [45,46,50], was analyzed in mdx and
dysf−/− myoﬁber nuclei in response to halofuginone. In freshly
prepared myoﬁbers, MyoD expression was observed in an average 1
nucleus per myoﬁber (data not shown). These numbers increased
in all myoﬁbers at 24 h and continued to rise at 48 h, conﬁrming the
activity of the attached satellite cells during the incubation periods
(Fig. 3). The number of MyoD-positive nuclei per myoﬁber was approx-
imately twofold higher in the halofuginone-treatedmdxmyoﬁbers than
in the control at both time points (Fig. 3B), and approximately 40%
higher at 48 h in dysf−/−myoﬁbers (Fig. 3C).
3.2. The increase in cell-cycle activity under halofuginone treatment is
mediated via the MAPK/ERK pathway
The MAPK/ERK pathway is activated during early events of
myoblast proliferation; it has been shown to be activated in mdx
myoblasts and to mediate halofuginone's inhibitory effects onSmad3 phosphorylation [36]. We therefore evaluated whether this
signaling pathway is affected by halofuginone in dysf−/− muscle cells
as well, and whether it mediates the halofuginone-dependent cell-
cycle activity of satellite cells in single myoﬁbers. Single myoﬁbers
were derived from the gastrocnemius muscle of 6-week-old dysf−/−
mice and immediately incubated, or not, with 10 nM halofuginone for
1 and 2 h. The single myoﬁbers were ﬁxed and reacted with antibody
against the phosphorylated form of MAPK/ERK (Fig. 4A). Some
myoﬁber-attached cells were already expressing phospho-MAPK/ERK
at time zero (i.e., freshly prepared myoﬁbers), suggesting some cell
activity which could result from the preparation process. The number
of cells expressing phospho-MAPK/ERK per myoﬁber increased within
1 h in the nontreated myoﬁbers and remained the same at 2 h
(Fig. 4B). In the halofuginone-treated myoﬁbers, the number of cells
expressing phospho-MAPK/ERK per myoﬁber was higher than that in
nontreated ones at 1 h and remained higher at 2 h of incubation.
The effect of halofuginone on MAPK/ERK phosphorylation was also
evaluated in primary myoblasts derived from dysf−/−mice at various
time points. Phospho-MAPK/ERK levels (P-p42/44) were 2.2- and
2.5-fold higher in the halofuginone-treated cells than in controls after
60 and 120 min, respectively, and dropped back to control levels after
180 min (Fig. 4C). A combined treatment of halofuginone with UO126,
a speciﬁc inhibitor ofMAPK/ERKphosphorylation, for 60min caused ap-
proximately threefold decrease in phospho-MAPK/ERK levels compared
to halofuginone alone, down to the levels in nontreated myoblasts
(Fig. 4D). Moreover, in dysf−/− myoﬁbers treated with halofuginone
for 18 h, the increase in BrdU-positive nuclei per myoﬁber was
attenuated in the presence of UO126 (Fig. 4E); numbers remained com-
parable to those in control nontreated myoﬁbers. This suggested that
the MAPK/ERK pathway is required for halofuginone-induced satellite
cell entrance into the cell cycle.
3.3. Halofuginone promotes the survival of cultured dysf−/− single
myoﬁbers and myoblasts
In light of the observed rise in cell-cycle markers in dysf−/− satellite
cells, we tested whether halofuginone affects apoptosis levels in the
dysf −/− muscle cells as it does in the mdx muscle [26]. Freshly
prepared single myoﬁbers derived from gastrocnemius muscle of
6-week-old dysf−/−mice were immediately incubated with or without
10 nM halofuginone for 24 h. The myoﬁbers were ﬁxed and reacted,
side by side, with antibodies against the pro-apoptotic marker Bax
and the anti-apoptotic marker Bcl2. The nontreated myoﬁbers exhibit-
ed high levels of Bax (Fig. 5Aa), whereas the halofuginone-treated sin-
gle ﬁbers showed markedly decreased levels (Fig. 5Ac). A reciprocal
effect was observed for Bcl2; its levels were low in the untreated
myoﬁbers (Fig. 5Ab) and increased in response to halofuginone
(Fig. 5Ad). Western blot analysis of Bax levels (normalized to YY1) in
these single myoﬁbers revealed that halofuginone decreased Bax levels
threefold compared to control nontreated myoﬁbers (Fig. 5B). The
high levels of Bax observed in single myoﬁbers derived from untreated
dysf −/−mice raised the possibility that their associated satellite cells
undergo apoptosis, which is reduced by halofuginone. To test this,
dysf−/− primary myoblasts were incubated for 24 h with or without
halofuginone, and then analyzed for Bax protein levels (normalized to
YY1; Fig. 5C). Densitometry analysis revealed that Bax levels were
twofold lower in the halofuginone-treated cells compared to controls.
3.4. The increase in cell survival under halofuginone treatment is mediated
by the PI3K/Akt pathway in dysf−/−muscle cells
Halofuginone has been shown to increase Akt phosphorylation
levels in myoblasts [36], and to be required for muscle cell survival
in mdx mice [26]. Single myoﬁbers prepared from dysf−/− mice
were immediately incubated with or without 10 nM halofuginone
for 1 and 2 h, and immunostained for the phosphorylated form of
Fig. 2. PHH3 expression in cells associatedwith C57 and dysf−/−myoﬁbers. Singlemyoﬁbers prepared from gastrocnemius of 6-week-old C57 and dysf−/−micewere untreated (Control)
or treated with 10 nM halofuginone (Halo) for 24 and 48 h, and then immunostained for PHH3. (A) Micrographs of single myoﬁbers. Nuclei were stained with DAPI. Arrows indicate
PHH3-positive nuclei, presumably satellite cells. (B) Quantitation analysis of PHH3-positive cells per myoﬁber in untreated and halofuginone-treated C57 myoﬁbers. (C) Quantitation
analysis of PHH3-positive cells in dysf −/−myoﬁbers. In the 24 h treatment, the rise in the number of PHH3-positive cells treated with halofuginone was near signiﬁcance (P= 0.053).
*Signiﬁcant difference at 48 h time point (n = 30; P b 0.05). Please note the different y-axis scales in B and C.
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on single myoﬁbers at both time points (Fig. 6A). Whereas the num-
ber of phospho-Akt-positive cells in control myoﬁbers remained con-
stant at both time points (but signiﬁcantly higher than at time 0), the
number of phospho-Akt-positive cells was higher in halofuginone-
treated vs. control myoﬁbers at 1 h and continued to rise, becoming
signiﬁcantly higher after 2 h (Fig. 6B).
The level of phosphorylated Akt in the presence of halofuginone
was evaluated in dysf−/− primary myoblasts at various time points.
Akt phosphorylation levels were higher in the halofuginone-treated
myoblasts at 60 min, and highest at 120 min relative to controls, then
declined back to control levels at 180 min (Fig. 6C).
The requirement for the PI3K/Akt pathway in halofuginone-
dependent cell survival was tested in dysf −/− primary myoblasts.
Treatment with halofuginone for 60 min decreased Bax levels by half,
whereas Akt phosphorylation levels increased 2.5-fold compared tothose in the control untreated cells (Fig. 6D, E). However, the combined
treatment of Ly294002, a speciﬁc inhibitor of Akt phosphorylation, with
halofuginone abolished halofuginone's effect and caused a twofold
increase in Bax levels compared to controls. Akt phosphorylation levels
were reduced ﬁvefold in control cells by Ly294002 addition, and over
15-fold in the presence of halofuginone compared to halofuginone-
treated cells alone.
4. Discussion
Satellite cells are themain, if not the sole source for myoblasts in the
regenerating muscle. As such, their ability to enter the cell-cycle and
differentiate tomyoblasts is of high importance for any injury in general
and for MDs in particular. The results of this study show that
halofuginone directly promotes cell-cycle progression of freshly
isolated myoﬁber-attached satellite cells in the mdxmouse model for
Fig. 3. Halofuginone increases the number of MyoD-positive nuclei onmdx and dysf −/−myoﬁbers. (A) Micrographs of single myoﬁbers derived from gastrocnemius of 6-week-oldmdx
and dysf −/−mice. Myoﬁbers were untreated (Cont) or treated with 10 nM halofuginone (Halo) for 24 and 48 h, and then reacted with antibody against MyoD. Nuclei were stained
with DAPI. Arrows indicate MyoD-positive nuclei. Note the abundance of MyoD-positive nuclei associated with the mdxmyoﬁber in the 48 h Halo treatment. Quantitative analysis of
MyoD-positive cells per myoﬁber in untreated and treated single myoﬁbers derived from mdx (B) or dysf −/− (C) mice. *Signiﬁcant difference within each time point (n = 30) at
P b 0.05. Please note the different y-axis scales in B and C.
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model for dysferlinopathy – with late onset and mild ﬁbrosis. In addi-
tion, in support of our earlier studies using mdx mice [26], this study
shows halofuginone's promotive effect on muscle cell survival in
the dysf−/−mouse. Taken together, the results of this study suggest a
direct positive role for halofuginone in ameliorating the pathology of
dystrophic muscles, regardless of the mutation.Cell-cycle activity of satellite cells was analyzed in single myoﬁbers.
Although cultured, these freshly prepared myoﬁbers present the
most accurate and in vivo-like cell system for investigations of satellite
cell behavior [50]. In the dystrophicmice, the higher BrdU incorporation
and PHH3 expression in the halofuginone-treated myoﬁbers vs.
controls, mark an increased effect of halofuginone on cell cycle
events in the satellite cells [46,51]. No apparent effect of halofuginone
Fig. 4. Halofuginone increases the phosphorylation levels of MAPK/ERK in dysf −/− muscle cells. (A) Phosphorylated MAPK/ERK expression in single-myoﬁber-associated cells.
Myoﬁbers isolated from the gastrocnemius of 6-week-old mice were untreated (Cont) or treated with 10 nM halofuginone (Halo) for various times, and then immunostained for
phospho-MAPK/ERK (P-MAPK/ERK). Nuclei were stained with DAPI. (B) Quantitation analysis of P-MAPK/ERK-positive cells (P-MAPK/ERK+) per myoﬁber in control and
halofuginone-treated dysf−/−myoﬁbers (n = 30). Different letters represent statistically signiﬁcant differences between all treatments at P b 0.05. (C) Myoblasts derived from hind-
leg muscle of 6-week-old dysf −/− mice were incubated in the presence or absence of 10 nM halofuginone for various times, or in the presence or absence of UO126 (20 μM) for
60 min (D). Expression levels of phospho-MAPK/ERK (P-p42/44) were analyzed by Western blot. Densitometry analysis for levels of phosphorylated proteins was normalized to total
p42/44 and is presented as fold induction relative to controls at each time point (C), or relative to control nontreated cells (D). C, Control; H, halofuginone. *Signiﬁcant difference within
treatments at P b 0.05 (n = 3). (E) The MAPK/ERK pathway is required for halofuginone-induced increase in BrdU incorporation. Myoﬁbers were treated as in (A) with or without the
addition of UO126 and/or halofuginone for 18 h. BrdU was added for the last 6 h and myoﬁbers were then stained for BrdU presence in myoﬁber-attached nuclei. BrdU-positive nuclei
were counted (n = 30 myoﬁbers) and results are presented as fold induction of control nontreated myoﬁbers. *Signiﬁcant difference at P b 0.05. UO, UO126, Halo, halofuginone.
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tial effect of halofuginone on satellite cells in favor of dystrophic mus-
cles with chronic inﬂammation and ﬁbrosis vs. Wt, in agreement with
previous reports [17,33,34]. In addition, the cell cycle activity of satellite
cells was reported to be higher in dystrophic muscles than in Wt mus-
cles [47–49]. The promotive effect of halofuginone on the cell-cycle
activity of satellite cells of dystrophic myoﬁbers was also reﬂected
in the higher number of nuclei expressing MyoD. MyoD and Myf5
are the ﬁrst myogenic regulatory factors that mark the entrance of
quiescent satellite cells into the myogenic program [46,52]. Together,
the results suggest that halofuginone has the capacity to directly affect
dystrophic myoﬁbers and increase the cell cycle activity and myogenic
proliferation of their attached satellite cells.Some differences were noted in the myoﬁbers derived from the
different MD mouse models. More BrdU-positive nuclei were observed
in the control dysf−/− vs. mdx myoﬁbers at 18 h, which might be due
to disease severity. At least with regard to dystrophin disorder, reduced
cell-cycle entrance has been reported for DMD myoblasts [53] and
for mdx myoblasts with severe phenotype [54]. Indeed, mdx muscle
possesses reduced NO synthase activity, and thereby low production
of NOwhich is crucial for satellite cell activation [5,6]. However, the dif-
ferent kinetics of BrdU incorporation and PHH3 expression in the mdx
vs. dysf−/−myoﬁber-attached satellite cells implies a longer cell cycle
in the latter. This longer cell cycle in dysf−/− cells could explain the
mild or nonexistent effect of halofuginone on cell-cycle events and
MyoD expression in these cells at 24 h, with a noticeable effect again
Fig. 5.Halofuginone's effect on the expression levels of pro- and anti-apoptotic markers in dysf −/−muscle cells. (A) Single myoﬁbers were prepared from 6-week-old dysf −/−mice and
immediately immunostained side by side for either Bax (a,c) or Bcl2 (b,d) under similar conditions. Nuclei were stained with DAPI. Note the lower Bax and higher Bcl2 intensity levels in
myoﬁbers treated with halofuginone and the reciprocal results in their untreated counterparts. Myoﬁbers (B) or myoblasts (C) derived from dysf −/− gastrocnemius were untreated or
treated with 10 nM halofuginone for 24 h. Bax protein levels in cell lysates were analyzed by Western blot. Densitometry analysis was normalized to total YY1 and is presented as fold
induction relative to control. *Signiﬁcant difference within treatments (n = 3) at P b 0.05.
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halofuginone's effect on cell-cycle markers and MyoD expression –
being more profound in themdx than dysf−/−mice. This implies a dif-
ference in the sensitivity of the satellite cells to halofuginone, which
might be dependent on the genetic disorder and/or disease progression
with regard to inﬂammation and ﬁbrosis. The mdx mice exhibit anearly-onset, severe phenotype at 6 weeks of age [33], the time of the
single-myoﬁber preparation; on the other hand, the dysf−/− mice
have a late-onset, mild phenotype, and while lacking the dysferlin
gene, they still possess a structurally intact and stable dystrophin-
glycoprotein complex in themuscles [55].We previously reported a dis-
parity between these two mouse models with regard to halofuginone's
Fig. 6. Halofuginone increases Akt phosphorylation levels in single-myoﬁber-associated cells and primary myoblasts derived from dysf −/−mice. (A) Single myoﬁbers derived from gas-
trocnemius of 6-week-old dysf−/−mice were untreated (Cont) or treatedwith 10 nMhalofuginone (Halo) for 1 and 2 h, and then immunostained for phosphorylated Akt (P-Akt). Nuclei
were stainedwith DAPI. Arrows indicate P-Akt-positive cells associatedwith themyoﬁber. (B) Quantitation analysis of P-Akt-positive cells (P-Akt+) permyoﬁber in untreated and treated
dysf −/−myoﬁbers (n = 30). Different letters represent statistically signiﬁcant differences (P b 0.05). (C) Myoblasts derived from hind-leg muscles of 6-week-old dysf −/−mice were
incubated in the presence or absence of 10 nM halofuginone for various times. Phosphorylation levels of Akt were analyzed by Western blot. Densitometry analysis was normalized to
total Akt and is presented as fold induction relative to control at each time point. *Signiﬁcant difference within treatments (n = 3) at P b 0.05. C, Control; H, halofuginone. (D) dysf −/−
myoblasts were incubated with or without halofuginone (10 nM) in the presence or absence of Ly294002 (Ly, 25 μM) for 60 min and the levels of Bax or phosphorylated Akt (P-Akt)
were analyzed byWestern blot. (E) Densitometry analysis for Bax and P-Akt was normalized to YY1 and total Akt, respectively. Results are presented as fold induction relative to controls
(n = 3). Different letters represent statistically signiﬁcant differences (P b 0.05).
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progression [17].
Halofuginone has been reported to promote MAPK/ERK phosphory-
lation inmdxmyoblasts [36]. The MAPK/ERK pathway has been report-
ed to mediate myoblast proliferation [38,41]. Here, we demonstrate
halofuginone's promotive effect on phospho-MAPK/ERK levels insatellite cells attached to freshly prepared single dysf−/− myoﬁbers
at as early as 1 h of incubation, suggesting halofuginone's effect on
early cell-cycle events in these cells. The blockage of halofuginone-
induced phosphorylation in dysf−/−myoblasts and BrdU incorporation
in dysf−/− myoﬁber-attached satellite cells by a pharmacological
MAPK/ERK inhibitor, UO126, suggest the requirement of this pathway
10 H. Barzilai-Tutsch et al. / Biochimica et Biophysica Acta 1862 (2016) 1–11to mediate the effects of halofuginone on cell cycle progression. The
phospho-MAPK/ERK pathway has been reported to mediate the inhibi-
tory effect of halofuginone on the TGFβ/Smad3 pathway [36]; the latter
pathway has been shown to interfere with the muscle's regenerative
capacity [56] and myogenic proliferation [57,58].
In many MDs with sarcolemmal deﬁciencies, including CMD and
DMD, apoptosis has been found to precede necrosis, the leading cause
of myoﬁber degradation. A decline in apoptosis accompanied by a
higher level of cell-cycle entrance can play a major role in improving
muscle regeneration and function. Recently, halofuginone has been
shown to increase the survival of satellite cells in the mdx muscle
in vivo and in cultured primary myoblasts and isolated myoﬁbers [26].
Here, we demonstrate a similar effect of halofuginone on the survival
of freshly isolated myoﬁbers and primary myoblasts derived from
6-week-old dysf −/−mice, before or at very early stages of the disease.
This was reﬂected in: (a) the decline in Bax protein expression levels
in myoﬁbers and myoblasts, and upregulation of Bcl2 levels in
myoﬁbers to levels comparable to those derived from mdx mice
(Fig. 5); (b) the time-dependent increase in Akt phosphorylation levels
in dysf−/− singlemyoﬁbers and primarymyoblasts; (c) the requirement
for the PI3K/Akt pathway to mediate halofuginone-induced effects on
muscle cell survival. The PI3K/Akt pathway has been shown to attenu-
ate apoptotic processes in various cell types, including skeletal muscle
[59–61], and to be required for muscle cell survival in mdx mice [26].
Collectively, these and previous data suggest that the promotive effect
of halofuginone on muscle cell survival is mediated by the PI3K/Akt
pathway and is common to all MDs, regardless of their onset or
progression rate.
Our previous and current results suggest that halofuginone's effects
on muscle cell proliferation and survival are directly mediated by the
MAPK/ERK and PI3K/Akt pathways. Nevertheless, it is conceivable that
these pathways also indirectly affect halofuginone's actions, at least in
part, via inhibition of the TGFβ/Smad3 pathway [36]. The TGFβ/Smad3
pathway has opposite effects on muscle cells and ﬁbroblasts: it medi-
ates the decrease in muscle cell survival and proliferation [58,62–64],
but it is also involved in increasing the proliferation of ﬁbroblasts and
their differentiation to myoﬁbroblasts, as well as their survival in
dystrophic muscles [27,28,35]. These TGFβ/Smad3-mediated effects
are inhibited by halofuginone in various tissues, including muscle
[17,27,65,66], and therefore could explain this compound's differential
and cell-type-speciﬁc effects on cell-cycle events and cell survival.
In conclusion, the data place halofuginone as an agent with a dual
role in dystrophic muscle tissue. It functions as an anti-ﬁbrotic agent
regardless of the disease disorder, yet acts in a cell-speciﬁc manner
with regard to cell-cycle progression and cell survival. Halofuginone
inhibits cell proliferation and increases apoptosis of myoﬁbroblasts,
but it also enhances the cell-cycle activity of satellite cells along with
muscle cell survival, regardless of MD type. The balance between
these activities leads to the overall net effect of halofuginone on ﬁbrosis,
muscle regeneration and function. These effects are of the utmost
importance as it is well known that in MDs in general, and in DMD in
particular, repetitive cycles of degeneration–regeneration in a continu-
ous attempt to deplete damaged myoﬁbers and reconstruct healthy
ones, exhaust the satellite cell population, impairing its proliferative or
regenerative capacity.
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